<DOC>
	<DOCNO>NCT02172209</DOCNO>
	<brief_summary>Trial ass effect food pharmacokinetics extent absorption single dose BI 10773 tablet healthy subject</brief_summary>
	<brief_title>Bioavailability Pharmacokinetics BI 10773 Tablet Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( BP , HR ) , 12lead ECG , clinical laboratory test Age ≥ 18 Age ≤ 55 year BMI ≥ 18.5 BMI ≤ 29.9 kg/m2 Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation Any finding medical examination ( include BP ( blood pressure ) , PR ( pulse rate ) ECG ( electrocardiogram ) ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g . repeat demonstration QTc interval &gt; 450 MS ) A history additional risk factor torsade de pointes ( e.g . heart failure , hypokalemia , family history Long QT Syndrome ) Elevated urinary glucose level screen ( &gt; 15 mg/dl ; &gt; 0.83 mmol/L )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>